Genital Shedding of Herpes Simplex Virus Among Symptomatic and Asymptomatic Persons With HSV-2 Infection | Infectious Diseases | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.212.130. Please contact the publisher to request reinstatement.
1.
Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment.  J Clin Invest. 1997;99(5):1092-10979062368PubMedGoogle ScholarCrossref
2.
Mertz KJ, Trees D, Levine WC,  et al; Genital Ulcer Disease Surveillance Group.  Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities.  J Infect Dis. 1998;178(6):1795-17989815237PubMedGoogle ScholarCrossref
3.
Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection.  Bull World Health Organ. 2008;86(10):805-81218949218PubMedGoogle ScholarCrossref
4.
Centers for Disease Control and Prevention (CDC).  Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years—United States, 2005-2008.  MMWR Morb Mortal Wkly Rep. 2010;59(15):456-45920414188PubMedGoogle Scholar
5.
Wald A, Zeh J, Selke S,  et al.  Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.  N Engl J Med. 2000;342(12):844-85010727588PubMedGoogle ScholarCrossref
6.
Mertz GJ. Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission.  J Infect Dis. 2008;198(8):1098-110018783317PubMedGoogle ScholarCrossref
7.
Schiffer JT, Abu-Raddad L, Mark KE,  et al.  Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model.  Sci Transl Med. 2009;1(7):7ra1620161655PubMedGoogle ScholarCrossref
8.
Magaret AS, Johnston C, Wald A. Use of the designation “shedder” in mucosal detection of herpes simplex virus DNA involving repeated sampling.  Sex Transm Infect. 2009;85(4):270-27519211593PubMedGoogle ScholarCrossref
9.
Mark KE, Wald A, Magaret AS,  et al.  Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults.  J Infect Dis. 2008;198(8):1141-114918783315PubMedGoogle ScholarCrossref
10.
Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir.  Ann Intern Med. 1996;124(1 pt 1):8-157503497PubMedGoogle ScholarCrossref
11.
Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera.  J Clin Microbiol. 1988;26(4):662-6672835389PubMedGoogle Scholar
12.
Ryncarz AJ, Goddard J, Wald A, Huang ML, Roizman B, Corey L. Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples.  J Clin Microbiol. 1999;37(6):1941-194710325351PubMedGoogle Scholar
13.
Magaret AS, Wald A, Huang ML, Selke S, Corey L. Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa.  J Clin Microbiol. 2007;45(5):1618-162017329447PubMedGoogle ScholarCrossref
14.
Corey L, Holmes KK. Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention.  Ann Intern Med. 1983;98(6):973-9836344713PubMedGoogle ScholarCrossref
15.
Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection.  Ann Intern Med. 1994;121(11):847-8547978697PubMedGoogle ScholarCrossref
16.
Phipps WSM, Saracino M, Magaret A,  et al.  Persistent genital herpes simplex virus-2 shedding years following the first clinical episode.  J Infect Dis. 2011;203(2):180-18721288817PubMedGoogle ScholarCrossref
17.
Diggle P. Analysis of Longitudinal Data. 2nd ed. New York, NY: Oxford University Press; 2002
18.
Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes.  Ann Intern Med. 1992;116(3):197-2021309413PubMedGoogle ScholarCrossref
19.
Zhu J, Koelle DM, Cao J,  et al.  Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation.  J Exp Med. 2007;204(3):595-60317325200PubMedGoogle ScholarCrossref
20.
Fleming DT, McQuillan GM, Johnson RE,  et al.  Herpes simplex virus type 2 in the United States, 1976 to 1994.  N Engl J Med. 1997;337(16):1105-11119329932PubMedGoogle ScholarCrossref
21.
Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations.  BMJ. 1994;309(6965):1325-13297866079PubMedGoogle ScholarCrossref
22.
Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections.  N Engl J Med. 1995;333(12):770-7757643884PubMedGoogle ScholarCrossref
23.
Sucato G, Wald A, Wakabayashi E, Vieira J, Corey L. Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region.  J Infect Dis. 1998;177(4):1069-10729534984PubMedGoogle ScholarCrossref
24.
Leone P, Abudalu M, Mitha E, Gani M, Zhou W, Hamed K. One-day famciclovir vs placebo in patient-initiated episodic treatment of recurrent genital herpes in immunocompetent black patients.  Curr Med Res Opin. 2010;26(3):653-66120070143PubMedGoogle ScholarCrossref
25.
Bochud PY, Magaret AS, Koelle DM, Aderem A, Wald A. Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus type 2 infection.  J Infect Dis. 2007;196(4):505-50917624834PubMedGoogle ScholarCrossref
26.
Casrouge A, Zhang SY, Eidenschenk C,  et al.  Herpes simplex virus encephalitis in human UNC-93B deficiency.  Science. 2006;314(5797):308-31216973841PubMedGoogle ScholarCrossref
27.
Celum C, Wald A, Lingappa JR,  et al; Partners in Prevention HSV/HIV Transmission Study Team.  Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.  N Engl J Med. 2010;362(5):427-43920089951PubMedGoogle ScholarCrossref
28.
Lingappa JR, Hughes JP, Wang RS,  et al.  Estimating the impact of HIV-1 plasma RNA reductions on heterosexual HIV-1 transmission risk.  PLoS One. 2010;5(9):e12598Google ScholarCrossref
29.
Cone RW, Hobson AC, Brown Z,  et al.  Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women.  JAMA. 1994;272(10):792-7968078144PubMedGoogle ScholarCrossref
30.
Corey L, Wald A, Patel R,  et al; Valacyclovir HSV Transmission Study Group.  Once-daily valacyclovir to reduce the risk of transmission of genital herpes.  N Engl J Med. 2004;350(1):11-2014702423PubMedGoogle ScholarCrossref
31.
Melville J, Sniffen S, Crosby R,  et al.  Psychosocial impact of serological diagnosis of herpes simplex virus type 2: a qualitative assessment.  Sex Transm Infect. 2003;79(4):280-28512902574PubMedGoogle ScholarCrossref
32.
Wald A, Langenberg AG, Link K,  et al.  Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women.  JAMA. 2001;285(24):3100-310611427138PubMedGoogle ScholarCrossref
33.
Wald A, Krantz E, Selke S, Lairson E, Morrow RA, Zeh J. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition.  J Infect Dis. 2006;194(1):42-5216741881PubMedGoogle ScholarCrossref
34.
Guerry SL, Bauer HM, Klausner JD,  et al.  Recommendations for the selective use of herpes simplex virus type 2 serological tests.  Clin Infect Dis. 2005;40(1):38-4515614690PubMedGoogle ScholarCrossref
Original Contribution
April 13, 2011

Genital Shedding of Herpes Simplex Virus Among Symptomatic and Asymptomatic Persons With HSV-2 Infection

Author Affiliations

Author Affiliations: Departments of Medicine (Drs Johnston, Corey, and Wald and Ms Tronstein), Laboratory Medicine (Drs Huang, Magaret, Corey, and Wald and Ms Selke), and Epidemiology (Dr Wald), University of Washington, Seattle; Vaccine and Infectious Disease Institute (Drs Johnston, Huang, Magaret, Corey, and Wald), and Program in Biostatistics (Dr Magaret), Fred Hutchinson Cancer Research Center, Seattle, Washington; and Westover Heights Clinic, Portland, Oregon (Ms Warren).

JAMA. 2011;305(14):1441-1449. doi:10.1001/jama.2011.420
Abstract

Context Since herpes simplex virus type 2 (HSV-2) antibody tests have become commercially available, an increasing number of persons have learned that they have genital herpes through serologic testing. The course of natural history of HSV-2 in asymptomatic, seropositive persons is uncertain.

Objective To evaluate the virologic and clinical course of HSV genital shedding among individuals with symptomatic and asymptomatic HSV-2 infection.

Design, Setting, and Participants Cohort of 498 immunocompetent HSV-2–seropositive persons enrolled in prospective studies of genital HSV shedding at the University of Washington Virology Research Clinic, Seattle, and Westover Heights Clinic, Portland, Oregon, between March 1992 and April 2008. Each participant obtained daily self-collected swabs of genital secretions for at least 30 days.

Main Outcome Measure The rate of viral shedding measured by quantitative real-time fluorescence polymerase chain reaction for HSV DNA from genital swabs.

Results Herpes simplex virus type 2 was detected on 4753 of 23 683 days (20.1%; 95% confidence interval [CI], 18.3%-22.0%) in 410 persons with symptomatic genital HSV-2 infection compared with 519 of 5070 days (10.2%; 95% CI, 7.7%-13.6%) in 88 persons with asymptomatic infection (P < .001). Subclinical shedding rates were higher in persons with symptomatic infection compared with asymptomatic infection (2708 of 20 735 days [13.1%; 95% CI, 11.5%-14.6%) vs 434 of 4929 days [8.8%; 95% CI, 6.3%-11.5%]) (P < .001). However, the amount of HSV detected during subclinical shedding episodes was similar (median, 4.3 [interquartile range, 3.1-5.6] log10 copies in the symptomatic infection group vs 4.2 [interquartile range, 2.9-5.5] in the asymptomatic infection group, P = .27). Days with lesions accounted for 2045 of 4753 days (43.0%; 95% CI, 39.8%-46.5%) with genital viral shedding among persons with symptomatic genital HSV-2 infection compared with 85 of 519 days (16.4%; 95% CI, 11.2%-23.9%) among persons with asymptomatic infection (P < .001).

Conclusion Persons with asymptomatic HSV-2 infection shed virus in the genital tract less frequently than persons with symptomatic infection, but much of the difference is attributable to less frequent genital lesions because lesions are accompanied by frequent viral shedding.

×